Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- TRILINK BIOTECHNOLOGIES, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- JTZNJ1K5HUA4
- Solicitation number
- PHS2005-2
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The long-term objective of this proposal is to provide a new and significantly improved "hot start" method for carrying out the polymerase chain reaction (PCR) for amplification, manipulation, and/or detection of DMA. "Hot start" PCR is widely used in molecular biology and biotechnology, and is also being applied to various types of genetic testing, clinical diagnostics, blood-screening, forensics and biodefense. These diverse health-related applications are predicated on the high specificity by which "hot start" PCR can amplify low-copy-number target DMA. Several strategies for conducting "hot start" PCR have been commercialized; however, none of these utilize chemically-modified synthetic oligonucleotides that offer significant potential advantages relative to currently available methods. The present proposal aims to assess the feasibility of using synthetic oligonucleotide primers which have a single phosphotriester-modification at the 3' end. This modification, which can be easily introduced with a reagent that is compatible with conventional DNA synthesizers, is intended to prevent 3' extension of the primer prior to a "hot start" step. In that step, the phosphotriester modification is intended to undergo thermally-induced, non-hydrolytic, fragmentation to generate a natural, unmodified internucleotide linkage that can then be recognized and extended by DNA polymerases. Chief among the envisaged advantages of the proposed new method for "hot start' PCR are its use with any thermal-stable DNA polymerase and buffer-pH, as well as greater reproducibility due to absolutely homogenous reaction conditions. It is also proposed that this new method when used in combination with currently available "hot start" DNA polymerases may provide greater levels of specificity and reliability for genetic testing, clinical diagnostics, blood-screening, forensics and biodefense since in all of these applications there are especially serious, adverse consequences of "false negatives" and "false positives". Synthetic routes are presented, as is the use of a simplified, 3'-modified-primer/duplex-DNA-target model system for studies using analytical separations by HPLC and PAGE, Each of the specific aims has a corresponding contingency plan to hopefully ensure completion of feasibility in a 6-month timeframe.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
10 SBIR/STTR records share this UEI (2005–2013). Reported award amounts total $3,594,388. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services
Agency intelligence
Department of Health and Human Services
Back to SBIR/STTR Research Awards